Af­ter ink­ing re­verse merg­er, Graphite Bio di­vests gene edit­ing pipeline to new­ly-formed biotech

Ka­mau Ther­a­peu­tics has emerged from stealth mode af­ter ink­ing a deal with Graphite Bio for its genome edit­ing as­sets. Ka­mau’s de­but comes less than a month af­ter Graphite en­tered a re­verse merg­er deal with Lenz Ther­a­peu­tics to form a new com­bined com­pa­ny.

San Fran­cis­co-based Ka­mau was co-found­ed by Stan­ford sci­en­tists Maria Grazia Ron­car­o­lo and Matthew Por­teus, who were al­so in­volved in cre­at­ing Graphite. Both re­searchers con­tributed to mak­ing Graphite’s ho­mol­o­gy di­rect­ed re­pair (HDR) plat­form tech­nol­o­gy, which Ka­mau now has the op­tion to ac­quire un­der the terms of the deal, the fi­nan­cial de­tails of which were undis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER